The stock of Sangamo Therapeutics Inc (NASDAQ: SGMO) has decreased by -0.49 when compared to last closing price of 2.05. Despite this, the company has experienced a -24.44% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-12 that Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
Is It Worth Investing in Sangamo Therapeutics Inc (NASDAQ: SGMO) Right Now?
The 36-month beta value for SGMO is at 1.10. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SGMO is 199.04M, and currently, shorts hold a 9.54% of that float. The average trading volume for SGMO on November 18, 2024 was 7.17M shares.
SGMO’s Market Performance
SGMO’s stock has seen a -24.44% decrease for the week, with a 121.57% rise in the past month and a 150.25% gain in the past quarter. The volatility ratio for the week is 18.27%, and the volatility levels for the past 30 days are at 21.03% for Sangamo Therapeutics Inc The simple moving average for the last 20 days is -1.66% for SGMO stock, with a simple moving average of 142.05% for the last 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with RBC Capital Mkts repeating the rating for SGMO by listing it as a “Sector Perform.” The predicted price for SGMO in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on November 03, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $1.50, previously predicting the price at $5. The rating they have provided for SGMO stocks is “Underperform” according to the report published on April 28th, 2023.
Wedbush gave a rating of “Outperform” to SGMO, setting the target price at $16 in the report published on February 27th of the previous year.
SGMO Trading at 51.26% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.83% of loss for the given period.
Volatility was left at 21.03%, however, over the last 30 days, the volatility rate increased by 18.27%, as shares surge +129.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +138.07% upper at present.
During the last 5 trading sessions, SGMO fell by -22.41%, which changed the moving average for the period of 200-days by +326.16% in comparison to the 20-day moving average, which settled at $2.08. In addition, Sangamo Therapeutics Inc saw 275.48% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -2.57 for the present operating margin
- 0.85 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -2.58. The total capital return value is set at -1.97. Equity return is now at value -156.42, with -82.26 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -4.12.
Currently, EBITDA for the company is -87.43 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 7.98. The receivables turnover for the company is 4.98for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
Conclusion
In conclusion, Sangamo Therapeutics Inc (SGMO) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
